##gff-version 3								
##gvf-version 1.10								
##species NCBI_Taxonomy_URI=http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
MN908947.3	.	snp	241	241	.	+	.	ID=ID_0;Name=c.C-25T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C-25T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	405	405	.	+	.	ID=ID_1;Name=p.K47R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=leader protein;mat_pep_desc=nsp1, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725297.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A140G;aa_name=p.K47R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	913	913	.	+	.	ID=ID_2;Name=p.S216S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C648T;aa_name=p.S216S;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	2110	2110	.	+	.	ID=ID_3;Name=p.N615N;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C1845T;aa_name=p.N615N;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	3037	3037	.	+	.	ID=ID_4;Name=p.F924F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C2772T;aa_name=p.F924F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	3267	3267	.	+	.	ID=ID_5;Name=p.T1001I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C3002T;aa_name=p.T1001I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	4900	4900	.	+	.	ID=ID_6;Name=p.H1545H;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C4635T;aa_name=p.H1545H;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	5097	5097	.	+	.	ID=ID_7;Name=p.N1611T;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=C;nt_name=c.A4832C;aa_name=p.N1611T;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	5388	5388	.	+	.	ID=ID_8;Name=p.A1708D;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C5123A;aa_name=p.A1708D;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	5986	5986	.	+	.	ID=ID_9;Name=p.F1907F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C5721T;aa_name=p.F1907F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	6954	6954	.	+	.	ID=ID_10;Name=p.I2230T;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=T;Variant_seq=C;nt_name=c.T6689C;aa_name=p.I2230T;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	7042	7042	.	+	.	ID=ID_11;Name=p.M2259I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=G;Variant_seq=T;nt_name=c.G6777T;aa_name=p.M2259I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	8603	8603	.	+	.	ID=ID_12;Name=p.F2780L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp4;mat_pep_desc=nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725300.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=T;Variant_seq=C;nt_name=c.T8338C;aa_name=p.F2780L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_13;Name=p.S3675del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=Q.8;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='3676del', 'F3677del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	11898	11898	.	+	.	ID=ID_14;Name=p.Q3878R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725303.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A11633G;aa_name=p.Q3878R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_13;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=Q.8;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_13;Name=p.F3677del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=Q.8;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', '3676del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_13;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=Q.8;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	11898	11898	.	+	.	ID=ID_14;Name=p.Q3878R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725303.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A11633G;aa_name=p.Q3878R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	12162	12162	.	+	.	ID=ID_15;Name=p.Q3966R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725304.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A11897G;aa_name=p.Q3966R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	14120	14120	.	+	.	ID=ID_16;Name=p.P4619L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C13856T;aa_name=p.P4619L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	14408	14408	.	+	.	ID=ID_17;Name=p.P4715L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C14144T;aa_name=p.P4715L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	14676	14676	.	+	.	ID=ID_18;Name=p.P4804P;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C14412T;aa_name=p.P4804P;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	15279	15279	.	+	.	ID=ID_19;Name=p.H5005H;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C15015T;aa_name=p.H5005H;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	15720	15720	.	+	.	ID=ID_20;Name=p.D5152D;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C15456T;aa_name=p.D5152D;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	16176	16176	.	+	.	ID=ID_21;Name=p.T5304T;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=T;Variant_seq=C;nt_name=c.T15912C;aa_name=p.T5304T;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	17615	17615	.	+	.	ID=ID_22;Name=p.K5784R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=helicase;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_acc=YP_009725308.1;ro=1;ao=2;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A17351G;aa_name=p.K5784R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6666666666666666;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	19011	19011	.	+	.	ID=ID_23;Name=p.D6249D;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3'-to-5' exonuclease;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only;mat_pep_acc=YP_009725309.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C18747T;aa_name=p.D6249D;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21137	21137	.	+	.	ID=ID_24;Name=p.K6958R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=2'-O-ribose methyltransferase;mat_pep_desc=nsp16_OMT, 2'-o-MT, produced by pp1ab only;mat_pep_acc=YP_009725311.1;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A20873G;aa_name=p.K6958R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_25;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1;citation=van Loon et al. (2021);comb_mutation='V70del', 'N501Y';function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P=0.01), longer symptom duration (P=0.02). Mean age was 36 yo.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1;citation=Snell et al. (2021);comb_mutation='V70del', 'N501Y';function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p=0.029), in London between March 13th 2020 and February 17th 2021 (400 B.1.1.7 cases out of 1470 total sequenced).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='V70del', 'N501Y';function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='V70del', 'N501Y';function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_27;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='V70del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_28;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y';function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_29;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y', 'P681H';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_27;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_29;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y', 'P681H';function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_29;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='V70del', 'N501Y', 'P681H';function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_29;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='V70del', 'N501Y', 'P681H';function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_27;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='V70del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_25;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_28;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_29;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y', 'P681H';function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_26;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_29;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del', 'N501Y', 'P681H';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_28;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/;citation=Avanzato et al. (2020);comb_mutation=;function_description=Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	"ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_31;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_31;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_31;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_25;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1;citation=van Loon et al. (2021);comb_mutation='H69del', 'N501Y';function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P=0.01), longer symptom duration (P=0.02). Mean age was 36 yo.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1;citation=Snell et al. (2021);comb_mutation='H69del', 'N501Y';function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p=0.029), in London between March 13th 2020 and February 17th 2021 (400 B.1.1.7 cases out of 1470 total sequenced).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='H69del', 'N501Y';function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='H69del', 'N501Y';function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_33;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='H69del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_34;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y';function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y', 'P681H';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_33;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y', 'P681H';function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='H69del', 'N501Y', 'P681H';function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='H69del', 'N501Y', 'P681H';function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_33;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='H69del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_25;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_34;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y', 'P681H';function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_32;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_35;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'N501Y', 'P681H';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_34;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/;citation=Avanzato et al. (2020);comb_mutation=;function_description=Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	"ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_31;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_30;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_31;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_31;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22319	22319	.	+	.	"ID=ID_36;Name=p.D253Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=G;Variant_seq=T;nt_name=c.G757T;aa_name=p.D253Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p = 0.0286).  Furthermore, the T cell response to the spike N501Y mutation common to all three of the current VOC was ablated.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1;citation=van Loon et al. (2021);comb_mutation='H69del', 'V70del';function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P=0.01), longer symptom duration (P=0.02). Mean age was 36 yo.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1;citation=Snell et al. (2021);comb_mutation='H69del', 'V70del';function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p=0.029), in London between March 13th 2020 and February 17th 2021 (400 B.1.1.7 cases out of 1470 total sequenced).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='H69del', 'V70del';function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='H69del', 'V70del';function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del';function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM);heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM);heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'P681H';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'P681H';function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='H69del', 'V70del', 'P681H';function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='H69del', 'V70del', 'P681H';function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'P681H';function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_38;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'P681H';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_37;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_41;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.27066;citation=Novazzi et al. (2021);comb_mutation='A570D';function_description=Partial sequencing of S gene reveals two cases of probable early 2021 B.1.1.7 lineage reinfection from non-B.1.1.7 original cases in Lombardy, with 45 to 90 days between infections (less than the typical 90 day guideline for this call). Patients were 56 and 58yo, immunocompenent, with one a former smoker with obesity and dyslipidemia. One case required intubation during first infection,  but presented with mild symptoms upon reinfection. The other case convalesced at home during the first episode, but required CPAP support  in the subacute clinical unit upon reinfection.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_42;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant raises PIWAS epitope score from 3.6% to 6.2% (improved immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	"ID=ID_43;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_42;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing statistically significant increased infection rate amongst the cells. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_43;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_42;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_42;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated that there is very little free energy change (ddG. -0.02 kcal/mol) for this variant (i.e. approx. same stability as wild type) ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_41;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.27066;citation=Novazzi et al. (2021);comb_mutation='N501Y';function_description=Partial sequencing of S gene reveals two cases of probable early 2021 B.1.1.7 lineage reinfection from non-B.1.1.7 original cases in Lombardy, with 45 to 90 days between infections (less than the typical 90 day guideline for this call). Patients were 56 and 58yo, immunocompenent, with one a former smoker with obesity and dyslipidemia. One case required intubation during first infection,  but presented with mild symptoms upon reinfection. The other case convalesced at home during the first episode, but required CPAP support  in the subacute clinical unit upon reinfection.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23271	23271	.	+	.	ID=ID_43;Name=p.A570D;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C1709A;aa_name=p.A570D;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='A570D';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_47;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D1118H';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='A570D';function_description=1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_47;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D1118H';function_description=1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation='P681H';function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_39;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='A570D';function_description=No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_46;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_47;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D1118H';function_description=1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ ;citation=Johnson et al. (2020);comb_mutation=;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_46;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'N501Y';function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1;citation=Lubinski et al. (2021);comb_mutation=;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'N501Y';function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='H69del', 'V70del', 'N501Y';function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='H69del', 'V70del', 'N501Y';function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_46;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_46;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation='D614G';function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'N501Y';function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_48;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_40;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del', 'V70del', 'N501Y';function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_46;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_49;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Mutation is predicted to lose the T cell epitope for people carrying DRB1*0301 and DRB1*0401,  but not for example in those who are DRB1*0701 or DRB1*1501 who would be predicted to show an enhanced response. This is also observed in a study of 26 each post-infection and post first dose HCWs.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_49;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	24914	24914	.	+	.	"ID=ID_47;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_49;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, hence this individual variant  is unlikely to contribute to cell entry fitness. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_47;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_47;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	25437	25437	.	+	.	ID=ID_50;Name=p.L15F;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=G;Variant_seq=T;nt_name=c.G45T;aa_name=p.L15F;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	27972	27972	.	+	.	ID=ID_51;Name=p.Q27X;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C79T;aa_name=p.Q27X;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	28048	28048	.	+	.	ID=ID_52;Name=p.R52I;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=G;Variant_seq=T;nt_name=c.G155T;aa_name=p.R52I;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	28095	28095	.	+	.	ID=ID_53;Name=p.K68X;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=1;dp=3;sample_size=3;Reference_seq=A;Variant_seq=T;nt_name=c.A202T;aa_name=p.K68X;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	28111	28111	.	+	.	ID=ID_54;Name=p.Y73C;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=A;Variant_seq=G;nt_name=c.A218G;aa_name=p.Y73C;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	28270	28270	.	+	.	ID=ID_55;Name=c.-3delA;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=TA;Variant_seq=T;nt_name=c.-3delA;aa_name=;vcf_gene=N;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	complex	28280	28282	.	+	.	ID=ID_56;Name=p.D3L;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GAT;Variant_seq=CTA;nt_name=c.GAT7_9CTA;aa_name=p.D3L;vcf_gene=N;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=subgenomic RNA expression;source=https://www.biorxiv.org/content/10.1101/2021.03.02.433156v1;citation=Parker et al. (2021);comb_mutation=;function_description=A noncanonical subgenomic RNA which could represent ORF9b is significantly enriched (~16x) in B.1.1.7 SARS-CoV-2 infections,  potentially as a result of a triple nucleotide mutation leading to amino acid substitution D3L  in nucleocapsid in this lineage which increases complementarity with the genomic leader sequence. ;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	complex	28280	28282	.	+	.	ID=ID_56;Name=p.D3L;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GAT;Variant_seq=CTA;nt_name=c.GAT7_9CTA;aa_name=p.D3L;vcf_gene=N;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=variant linear antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=At the epitope level, the D3L mutation reduces PIWAS signal in 1.5% of COVID patients (outliers reduce from 2.1% in wild type to 0.5% in mutant). In 3 of these patients (0.5% of the population), that alteration represents the strongest antigen signal and substantially reduces the PIWAS antigen score. In the B1.1.7 lineage this is largely counteracted by the S235F mutation, which increases epitope and antigen scores significantly in two individuals, for a net neutral effect at the population level.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	complex	28881	28883	.	+	.	ID=ID_57;Name=p.RG203KR;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=GGG;Variant_seq=AAC;nt_name=c.GGG608_610AAC;aa_name=p.RG203KR;vcf_gene=N;mutation_type=;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	28977	28977	.	+	.	ID=ID_58;Name=p.S235F;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=3;dp=3;sample_size=3;Reference_seq=C;Variant_seq=T;nt_name=c.C704T;aa_name=p.S235F;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=Q.8;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=variant linear antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Substantially increases epitope and antigen scores in 2 of 579 individuals (should increase immune response). In the B1.1.7 lineage this is largely counteracted by the D3L mutation, which decreases PIWAS signal significantly in 1.5% of COVID patients, for a net neutral effect at the population level.;heterozygosity=False;clade_defining=True;who_variant=Alpha;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
